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Background: The pathogenic p.Arg14del phospholamban (PLN) mutation has been identified in 12-15% of Dutch patients with 
arrhythmogenic right ventricular cardiomyopathy (ARVC) and/or dilated cardiomyopathy (DCM). The purpose of this study was to evaluate 
the additional value of right ventricular endomyocardial biopsy (RVEMB) to diagnose ARVC in these mutation carriers and detect PLN 
protein aggregates in cardiomyocytes.
methods: RVEMB-specimens from 23 mutation carriers (12 males, 11 females; mean [±SD] age at RVEMB 42 ± 12 years) were studied. 
Masson’s trichrome staining was used to determine the amount of fibrofatty replacement and residual myocytes, immunohistochemistry for 
PLN to visualize protein aggregation. All patients were evaluated using clinical ARVC and DCM criteria.
results: Histological examination showed fibrofatty replacement and myocyte loss consistent with ARVC in 17/23 (74%) patients (11/23 
(48%) major criterium; 6/23 (26%) minor criterium according to task force criteria). Immunohistochemical analysis revealed PLN aggregates 
in only 2/15 (13%) cases. By clinical evaluation before RVEMB, 11/23 (48%) patients were diagnosed with DCM, 2/23 (9%) with ARVC, 
2/23 (9%) with combined ARVC/DCM while 8/23 (35%) did not meet sufficient criteria for either DCM or ARVC. Interestingly, by adding 
RVEMB analysis, 5/23 (22%) additional patients were diagnosed with combined ARVC/DCM, and 4/23 (17%) with ARVC.
conclusion:  In PLN p.Arg14del mutation-related cardiomyopathy, fibrofatty replacement of the right ventricle was found in the majority of 
biopsies. Adding this finding may establish a definitive ARVC diagnosis and reveal the biventricular ARVC/DCM phenotype typical for this 
cardiomyopathy. PLN-immunohistochemical analysis in these RVEMB samples had a very low sensitivity for demonstration of PLN protein 
aggregates.
